STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Clinical trials for STAGE III HEPATOCELLULAR CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III HEPATOCELLULAR CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III HEPATOCELLULAR CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test radiation 'One-Two Punch' to rally Body's defenses against liver cancer
Disease control OngoingThis early-stage study is testing the safety and effectiveness of a two-step treatment for advanced liver cancer that cannot be surgically removed. First, patients receive a targeted radiation treatment directly to the liver tumor. Then, they receive two immunotherapy drugs desig…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Custom radiation doses target liver cancer more precisely
Disease control OngoingThis study tests whether customizing radiation doses for each patient's liver cancer can improve treatment results. Researchers are giving 42 patients with advanced, inoperable liver cancer precisely measured radiation doses directly to their tumors. The goal is to see if persona…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Personalized immune cells take aim at tough liver cancers
Disease control TerminatedThis early-stage study is testing a new treatment for advanced liver cancer that has come back or stopped responding to standard therapies. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack cancer cells, and then infuse them back into …
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New combo therapy trial offers hope for HIV patients with advanced cancers
Disease control OngoingThis is a small, early-stage safety study testing a combination of two cancer drugs, nivolumab and cabozantinib, in people living with HIV who have advanced solid tumors. The main goal is to see if the two-drug combination is safe and tolerable for this specific patient group. Re…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New drug combo tested for Tough-to-Treat liver cancer
Disease control OngoingThis study is testing whether a new drug called pevonedistat can help control advanced bile duct cancer that starts in the liver. It is being tested alone and in combination with two standard chemotherapy drugs (carboplatin and paclitaxel) in about 40 patients whose cancer has wo…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New drug duo aims to shrink tough liver tumors
Disease control OngoingThis study is testing if a combination of two drugs, regorafenib and durvalumab, can shrink tumors in people with high-risk liver cancer before they have surgery. The goal is to see if this pre-surgery treatment makes the cancer easier to remove and helps patients live longer. It…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Mar 10, 2026 12:52 UTC